Core Viewpoint - The article highlights the New Leaf Award, a global and comprehensive award focused on innovation in the bio-based sector, aimed at discovering, showcasing, and recognizing outstanding products and companies in the bio-based industry, often referred to as the "Oscar" of the bio-based sector [2]. Group 1: Award Information - The New Leaf Award includes categories such as Innovation Materials Award, Innovation Applications Award, Most Commercially Valuable Award, and Innovative Industry Solutions Award [3]. - The deadline for the fourth selection activity is March 13, 2026 [8]. Group 2: Company Profile - Yuan Yi (Tianjin) Biotechnology Co., Ltd. is a leading company in synthetic biology solutions, competing for the 2026 New Leaf Awards in the "Innovation Materials Award" and "Most Commercially Valuable Award" categories [3]. Group 3: Product Details - The company offers recombinant humanized collagen, which is 100% homologous to human collagen sequences, featuring high activity, low allergenicity, and the ability to support large-scale production and precise applications in various scenarios [9]. - The product is advantageous for promoting cell adhesion and enhancing cell repair functions, with high purity and low allergen rates, and it does not pose risks of endotoxin contamination [10]. Group 4: Applications and Benefits - In the medical aesthetics field, the heat-resistant properties of the gel prevent dissolution due to body temperature, ensuring longer retention at target sites, thus improving tissue repair and anti-aging effects [10]. - In skincare products, the heat-resistant gel can withstand emulsification temperatures above 80°C, preventing loss of activity during production and expanding the range of collagen skincare products [10]. - In the biomedical field, the heat-resistant collagen gel can endure high temperatures during sterilization and provide sustained moisture and repair barriers for high-temperature wounds, enhancing clinical treatment efficiency [10]. Group 5: Product Range - Yuan Yi Biotechnology has developed various types of collagen, including 18 different molecular weights, allowing for tailored solutions to multiple issues, achieving a self-research, self-production, and self-sales closed loop [10].

Core Viewpoint - The article discusses the strategic partnership between Lude Technology and Hanghua New Materials, focusing on the development of high-value utilization of brewing waste resources in the fields of bio-fermentation, functional feed, and functional food [2]. Group 1: Company Overview - Lude Technology, established in 2006, specializes in the resource utilization of high-water-content waste and has recently focused on bio-manufacturing, particularly in bio-fermentation feed [4]. - The newly established Lukan Bio-Technology (Hangzhou) Co., Ltd. has a registered capital of 30 million [4]. Group 2: Strategic Partnership - The partnership with Hanghua New Materials aims to leverage their strong R&D and industrialization capabilities in synthetic biology, enzyme preparations, and industrial strains development [5]. - Hanghua New Materials is a subsidiary of Hangzhou Shihua Group, which is focusing on advanced manufacturing, smart IoT, biomedicine, and new energy materials to promote urban industrial transformation and modernization [5].

Core Viewpoint - The bio-based 1,3-propanediol (PDO) industry in China is transitioning from "technology validation" to "scale production" by 2025, driven by the demand for green transformation in downstream markets such as textiles and cosmetics [2]. Group 1: PDO Production Capacity and Technological Advances - By 2025, multiple companies are accelerating the construction of large-scale production bases for bio-based PDO, with significant investments and technological breakthroughs [4][5]. - Companies like Qingda Zhixing and Heng Carbon Technology have successfully developed fermentation methods for PDO production, breaking the technological monopoly of foreign firms [5][6]. - Heng Carbon Technology has established a unique production base with an annual capacity of 15,000 tons, utilizing a revolutionary "three non-four no" technology that is highly environmentally friendly [6][7]. Group 2: Market Expansion and Applications - PDO is widely applicable in various industries, including polyester, cosmetics, polyurethane, pharmaceuticals, and coatings [10]. - The global bio-based PTT market, which utilizes PDO as a core monomer, is projected to grow from approximately 3.4 billion yuan in 2023 to 8.3 billion yuan by 2030, with a compound annual growth rate of 13.1% [13]. - Companies are forming strategic partnerships to create integrated industrial bases that enhance competitiveness in the bio-based PTT market [13][14]. Group 3: Emerging Companies and Innovations - New companies are emerging with innovative production techniques, such as Shandong Xiangchi Jianyuan Biotechnology, which is implementing advanced fermentation methods to enhance production efficiency [9]. - Zhongke Baiyijin has successfully produced bio-based PDO with a purity of 99.9% using biomass as a raw material [9]. - The industry is witnessing a structural expansion in downstream markets, particularly in textiles and cosmetics, benefiting from reduced raw material costs and increased production capacity [14].

Core Viewpoint - SynBioCon reports that the biomanufacturing company, Saito Bio, has announced a change in part of its fundraising investment projects, adjusting the total investment of the original project from 367 million yuan to 229 million yuan, and reallocating 124 million yuan to a new project focused on biosynthetic technology research and industrialization [3]. Group 1: Investment Project Changes - The new investment project, "Biosynthetic Technology Research and Industrialization Project," has a total investment of 237 million yuan, with the implementation led by its wholly-owned subsidiary, Jinweiduo, aiming to establish production lines for 1,000 tons/year of Tartrate Tylosin and 200 tons/year of Phosphate Tylosin [5]. - Tartrate Tylosin and Phosphate Tylosin are commonly used drugs for preventing and treating mycoplasma infections in animals, significantly reducing the incidence of respiratory diseases in livestock, indicating strong market demand [5]. Group 2: Company Background and Strategy - Established in 2010, Saito Bio was the first to utilize genetic engineering and synthetic biology for the large-scale production of steroid drug raw materials, becoming a leading supplier of steroid drug raw materials in China [5]. - In 2019, Saito Bio set a long-term industrial upgrade strategy to create a biomanufacturing enterprise integrating "pharmaceutical intermediates - active pharmaceutical ingredients - formulations," successfully producing five major steroid raw material series using synthetic biology [5]. Group 3: Strategic Collaborations - In 2024, the company formed a strategic partnership with AI pharmaceutical company, InSilico Medicine, to leverage cutting-edge AI technology and optimize key steps in the engineering transformation process for synthetic biology research and innovative drug development [6].

Core Viewpoint - The article emphasizes that China is poised to play a significant role in the future of biomanufacturing, which is expected to create an economic value exceeding $30 trillion by 2050, marking it as a core driver of the next industrial revolution [2][7]. Summary by Sections What is Biomanufacturing? - Biomanufacturing transforms living organisms, such as microorganisms and cells, into "smart factories" that produce various substances needed by humans. This process marks a fundamental shift from traditional manufacturing, which relies on fossil resources, to using renewable resources like sugar, straw, and carbon dioxide [2][3]. Importance of Biomanufacturing - Biomanufacturing is crucial for achieving carbon neutrality as it significantly reduces carbon emissions by utilizing renewable resources instead of fossil fuels. It allows for a broader range of raw materials and a greener manufacturing process, making factories resemble ecosystems [3]. - The potential for programmable manufacturing is immense, as scientists can design microorganisms to produce specific molecules, akin to writing code, thus unlocking vast possibilities [3]. Impact on Daily Life - In the food sector, cell-cultured meat and new food ingredients like microbial proteins are becoming mainstream. - The fashion industry is seeing innovations such as bio-silk from bacteria and biodegradable textiles from algae and fungi. - In construction, "bio-bricks" made from fungal mycelium can self-repair and absorb carbon dioxide, potentially transforming buildings into "green life forms." - Transportation is advancing with the production of aviation fuel from carbon dioxide, and biomanufacturing is also contributing to greener lubricants and tire rubbers. - In healthcare, biomanufacturing can streamline drug synthesis, enabling personalized medicine and potentially allowing hospitals to "print" drugs and organs [4]. Challenges and Future Trends - Biomanufacturing faces challenges such as the need for improved foundational capabilities in gene editing and enzyme engineering, difficulties in scaling from lab to industrial production, and the lack of a comprehensive policy and standards framework [5]. - Future trends include the integration of artificial intelligence in biomanufacturing, enabling rapid strain improvement, carbon cycling in manufacturing processes, and cross-industry collaborations that will create new industrial ecosystems [6]. Opportunities for China - China has advantages in fermentation capacity, industrial scale, and engineering experience. The government is actively promoting biomanufacturing as a new growth engine, positioning the country to take a leading role in this transformative industry [7].

Core Viewpoint - Synthetic biology is recognized as a disruptive force in the life sciences, providing innovative solutions to major challenges in health, energy, and the environment, and is positioned to create a trillion-dollar industry in China as part of the 14th Five-Year Plan [5][6]. Event Overview - The 2026 Fourth Synthetic Biology Industry Expo (SBC2026) will take place on April 17-18, 2026, at the Yangtze River International Conference Center in Nanjing, Jiangsu [2][8]. - The event is organized by BioValley, Bioeconomy, Shandong University, East China University of Science and Technology, and the National Key Laboratory of Microbial Technology at Shandong University [2]. Exhibition and Forum Highlights - SBC2026 aims to integrate deep technology with broad consumer engagement, covering the entire industry chain from strain design to end products, providing a comprehensive platform for industry insights [5]. - The expo will feature five main thematic venues, 14 cutting-edge topics, nearly 100 industry experts, and an exhibition area of 10,000 square meters, expecting 5,000 professional attendees [9][12]. Thematic Sessions - The event will include specialized forums on various topics such as: - Medical beauty and daily chemicals - Agriculture and natural products - Chemicals and materials - Food and nutrition - Medicine and health [12][31][36]. Notable Speakers and Topics - Keynote speakers include academicians and industry leaders discussing trends in DHA oil, food industry innovations, and the transition of synthetic biology from lab to commercialization [15][43]. - The agenda includes discussions on sustainable development in agriculture, innovations in food technology, and advancements in medical applications of synthetic biology [23][36][43]. Consumer Engagement - A unique consumer experience area will be established to showcase innovative products and ingredients directly to the public and distributors, illustrating how synthetic biology technologies are reshaping future consumption [5][6].

Core Viewpoint - The New Leaf Award, a prestigious global award in the bio-based industry, has launched its 2026 registration, aiming to recognize and showcase innovative products and companies in the sector [2]. Group 1: Award Categories - The New Leaf Award features four main categories: Innovation Materials Award, Innovation Application Award, Innovation Industry Solutions Award, and Most Commercially Valuable Award [4][22]. Group 2: Registration Timeline & Process - Registration for the 2026 New Leaf Award starts on December 1, 2025, and ends on March 13, 2026. The initial online voting will take place from March 16 to March 22, 2026, followed by online presentations and expert reviews from March 23 to March 27, 2026. The award ceremony will be held on May 21, 2026, during the 11th Bio-based Conference [6][9]. Group 3: Evaluation Criteria - The evaluation criteria for the awards include: - Innovation in Technology: 30% for Innovation Materials Award, 10% for Innovation Application Award, 20% for Innovation Industry Solutions Award - Innovation in Application: 10% for Innovation Materials Award, 30% for Innovation Application Award, 20% for Innovation Industry Solutions Award - Functionality: 25% for Innovation Materials Award, 25% for Innovation Application Award, 30% for Innovation Industry Solutions Award - Commercial Value: 20% for Innovation Materials Award, 20% for Innovation Application Award, 15% for Innovation Industry Solutions Award - Sustainability: 15% across all categories [10]. Group 4: Benefits of Participation - Participating companies will receive free publicity through the award process, which includes access to over 100 industry communication groups and a large audience for brand exposure. Award-winning companies will also be invited to the award ceremony, where they will receive a high-end trophy and certificate in front of industry leaders [11][12].

Core Viewpoint - The article discusses the environmental impact assessment (EIA) public announcement for Yifeng Jiatai (Mudanjiang) Biotechnology Development Co., Ltd.'s project to produce 30,000 tons/year of 1,3-propanediol (PDO) through batch fermentation [3]. Project Overview - Project Name: Yifeng Jiatai (Mudanjiang) Biotechnology Development Co., Ltd. Batch Fermentation Production of 30,000 tons/year of 1,3-propanediol (PDO) Project [5] - Location: Hualin Chemical Park, Mudanjiang [5] - Nature of Construction: New construction [5] - Construction Details: The project plans to build two production lines with an annual output of 15,000 tons of 1,3-propanediol each, utilizing batch fermentation technology, with supporting infrastructure to achieve a total production capacity of 30,000 tons/year [5] - Total Investment: 520 million yuan [5] - Company Background: Yifeng Jiatai was established on November 12, 2025, in Mudanjiang, Heilongjiang Province, with a legal representative named Ma Dexiang. The company's business scope includes feed production and various technical services [5].

Core Viewpoint - The article highlights a significant breakthrough in China's cell-cultured meat industry, with the establishment of the largest pilot plant for cell-cultured meat by Nanjing Zhouzi Future Food Technology Co., marking a key transition from laboratory research to engineering production [3][6]. Group 1: Company Achievements - Zhouzi Future is recognized as a pioneer in the cell-cultured meat sector in China, having developed the first cell-cultured meat in 2019 and founded in 2020 to advance industrialization [5]. - The company achieved the world's first 2000-liter bioreactor pilot production of cell-cultured pork in December 2025, establishing itself as a leader in this technology on an international scale [5][10]. - The pilot plant integrates various processes, including seed cell creation, serum-free medium development, and a comprehensive food safety system, with an annual production capacity of 10 to 50 tons of cell-cultured meat [6]. Group 2: Technological Innovations - Zhouzi Future has developed a dual research system focusing on both general products and innovative specialties, utilizing 3D printing technology to replicate the texture and flavor of traditional pork [7]. - The company has introduced unique products such as "honeycomb meat" and "meat clear soup jelly with crispy meat slices," showcasing the versatility of cell-cultured meat in various culinary applications [7]. Group 3: Industry Trends - The global cell-cultured meat industry is experiencing a surge in commercialization, with five countries approving products from ten companies, indicating a rapid acceleration in market acceptance [8]. - The regulatory landscape is evolving, with six new cell-cultured meat products gaining approval in 2025 alone, solidifying the foundation for large-scale commercial growth [8][10]. - Zhouzi Future's advancements position it to compete effectively in the global food technology and sustainable protein supply markets [10].

关键词 | 生物基大会 |青年科学家论坛 当新质 生产力成为高质量发展的关键引擎，当青年科技人才在创新发展中的生力军作用愈发凸显，如何发现青年之智？如何点燃创新之力？ 该论坛将收集 80个 创新申请报告，以 " 让生物基青年科学家被看见 " 为主旨，助力行业 10分钟 挖掘一个生物基领域的前沿技术 ，聚集原创，突 破边界， 对接人才与合作搭建一个高效交流平台。同时，为助力创新，青年科 学家论坛设置 现场评选 与奖金颁发 环节 。 扫码报名 | Bio-based 2026 请勾选：青年科学家论坛、科技成果展示 01 青年论坛概况： 主办单位 ： 浙江省全省生物基高分子材料重点实验室、 宁波德泰中研信息科技有限公司（ DT 新材料） 时间地点 ：2026年5月20日下午，上海 DT新材料旗下生物基和生物制造产业科技服务平台， 是行业最重要 的资源和信息枢纽之一 。至今为止，我们在生物基大会、非粮生物质论坛、合成 生物学与绿色生物制造论坛、材视等多场主创活动上举办多届青年主题论坛，已有 500+位 创新青年科学家线上线下分享前沿科技与进展，并促进产 业、投资和科研等多方交流、关注与对接。 往届DT新材料主办青年论 ...